Rocket Pharmaceuticals shares are trading lower. The company announced the FDA issued a Complete Response Letter for the License Application For KRESLADI and requested limited additional Chemistry Manufacturing and Controls information to complete its review.
Portfolio Pulse from Benzinga Newsdesk
Rocket Pharmaceuticals shares are trading lower after the FDA issued a Complete Response Letter for the License Application For KRESLADI, requesting additional Chemistry Manufacturing and Controls information.
June 28, 2024 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Rocket Pharmaceuticals shares are trading lower after the FDA issued a Complete Response Letter for the License Application For KRESLADI, requesting additional Chemistry Manufacturing and Controls information.
The FDA's Complete Response Letter indicates that Rocket Pharmaceuticals needs to provide additional information before approval, which delays the product's market entry and impacts investor sentiment negatively.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100